CervoMed (CRVO) Stock Price, News & Analysis

Company Overview

CervoMed Inc., a biotechnology company, engages in the development and commercialization of treatments for age-related neurologic disorders. Its lead drug candidate is neflamapimod, an orally administered small molecule brain penetrant for the treatment of dementia with Lewy bodies (DLB), Alzheimer's diseases, frontotemporal dementia, and ischemic stroke recovery. The company also develops EIP200 for central nervous system which is in preclinical trials. CervoMed Inc. was founded in 2010 and is headquartered in Boston, Massachusetts.

Key Stats

• Today's Range: $10.25 to $13.47
• 50-Day Range: $2.12 to $14.29
• 52-Week Range: $1.80 to $25.92
• Volume: 1.25 million shs
• Average Volume: 1.28 million shs
• Market Capitalization: $96.43 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $27.50
• Consensus Rating: Moderate Buy

CervoMed Stock Analysis - MarketRank™

CervoMed scored higher than 60% of companies evaluated by MarketBeat, and ranked 362nd out of 916 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 4.4 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

CervoMed has received a consensus rating of Moderate Buy. The company's average rating score is 2.89, and is based on 5 buy ratings, 1 hold rating, and 1 sell rating.

Amount of Analyst Coverage

CervoMed has been the subject of 6 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for CervoMed are expected to grow in the coming year, from ($1.88) to ($1.69) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of CervoMed is -5.46, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of CervoMed is -5.46, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

CervoMed has a P/B Ratio of 8.52. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 2.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

46.63% of the float of CervoMed has been sold short.

Short Interest Ratio / Days to Cover

CervoMed has a short interest ratio ("days to cover") of 0.6, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in CervoMed has recently increased by 190.70%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

CervoMed does not currently pay a dividend.

Dividend Growth

CervoMed does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

46.63% of the float of CervoMed has been sold short.

Short Interest Ratio / Days to Cover

CervoMed has a short interest ratio ("days to cover") of 0.6, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in CervoMed has recently increased by 190.70%, indicating that investor sentiment is decreasing significantly.

News and Social Media

• Score: 2.8 / 5
• News Sentiment: 0.06

News Sentiment

CervoMed has a news sentiment score of 0.06. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.62 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 5 news articles for CervoMed this week, compared to 2 articles on an average week.

Search Interest

51 people have searched for CRVO on MarketBeat in the last 30 days.

MarketBeat Follows

30 people have added CervoMed to their MarketBeat watchlist in the last 30 days. This is an increase of 2,900% compared to the previous 30 days.

Company Ownership

• Score: 1.7 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, CervoMed insiders have not sold or bought any company stock.

Percentage Held by Insiders

36.30% of the stock of CervoMed is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

Only 25.15% of the stock of CervoMed is held by institutions.

CRVO Stock Analysis - Frequently Asked Questions

How have CRVO shares performed this year?

CervoMed's stock was trading at $2.34 at the start of the year. Since then, CRVO stock has increased by 373.5% and is now trading at $11.08.
View the best growth stocks for 2025 here.

How were CervoMed's earnings last quarter?

CervoMed Inc. (NASDAQ:CRVO) announced its quarterly earnings results on Monday, March, 17th. The company reported ($0.80) EPS for the quarter, missing the consensus estimate of ($0.67) by $0.13. The company earned $2.16 million during the quarter, compared to analysts' expectations of $1.51 million. CervoMed had a negative net margin of 118.68% and a negative trailing twelve-month return on equity of 44.11%.

How do I buy shares of CervoMed?

Shares of CRVO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of CervoMed own?

Based on aggregate information from My MarketBeat watchlists, some other companies that CervoMed investors own include Zomedica (ZOM), Jumia Technologies (JMIA), Nano Dimension (NNDM), NVIDIA (NVDA), Broadcom (AVGO), Arista Networks (ANET) and e.l.f. Beauty (ELF).

Company Calendar

• Last Earnings: 3/17/2025
• Today: 4/05/2025
• Next Earnings (Estimated): 5/13/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Pharmaceutical preparations
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:CRVO
• Previous Symbol: NASDAQ:CRVO
• CIK: 1053691
• Web: diffusionpharma.com
• Phone: 14342200718
• Fax: 434-220-0722
• Employees: 4
• Year Founded: N/A

Price Target and Rating

• Average Stock Price Target: $27.50
• High Stock Price Target: $63.00
• Low Stock Price Target: $10.00
• Potential Upside/Downside: +148.2%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.89
• Research Coverage: 9 Analysts

Profitability

• EPS (Most Recent Fiscal Year): ($2.03)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: $-2,170,000.00
• Net Margins: -118.68%
• Pretax Margin: -118.68%
• Return on Equity: -44.11%
• Return on Assets: -39.81%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 15.04
• Quick Ratio: 15.04

Sales & Book Value

• Annual Sales: $7.14 million
• Price / Sales: 13.51
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $1.30 per share
• Price / Book: 8.52

Miscellaneous

• Outstanding Shares: 8,703,000
• Free Float: 3,930,000
• Market Cap: $96.43 million
• Optionable: Not Optionable
• Beta: 0.21